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Luana Calabrò8, Fausto Barbieri9, Antonio Santo10, Giuseppe Altavilla11,
Francesca Ambrosio12, Enrico Mini13, Enrico Vasile14, Floriana Morgillo15,
Alessandro Scoppola16, Carmelo Bengala17, Alessandro Follador18,
Natale Tedde19, Diana Giannarelli20, Giuseppe Lo Russo1 and
Fabiana Vitiello21
Abstract
Objectives: Never-smokers may be a distinct subgroup among patients with advanced non-small cell lung cancer,
appearing to benefit less from immunotherapy than smokers. We report results from never-smokers enrolled in the
Italian cohort of the nivolumab expanded access program in pre-treated patients with advanced squamous non-small
cell lung cancer.
Materials and methods: Nivolumab (3 mg/kg every 2 weeks for ł 24 months) was available on physician request.
Efficacy data included objective tumor response, date of progression, and survival information. Safety was monitored.
Results: Overall, 371 patients received at least one dose of nivolumab, including 31 never-smokers (8%). Objective
response rate, disease-control rate, and median overall survival were 23%, 45%, and 12.1 months (95% confidence
interval: 3.7–20.4), respectively, in never-smokers, and 18%, 47%, and 7.9 months (95% confidence interval: 6.2–9.6),
respectively, in the overall expanded access program population. Any-grade and grade 3–4 treatment-related adverse
events were reported in 12 (39%) and 3 (10%) never-smokers, respectively, and in 109 (29%) and 21 (6%) patients,
respectively, in the overall expanded access program population. Grade 3–4 treatment-related adverse events in non-
smokers were increased transaminases (n = 2; 6%) and diarrhea (n = 1; 3%). Treatment-related adverse events led to
treatment discontinuation in 4 non-smokers (17%) and in 26 patients (9%) overall.
Conclusion: Pre-treated never-smokers with advanced squamous non-small cell lung cancer in this Italian expanded
access program demonstrated efficacy and safety that were consistent with those in the overall expanded access
program population and clinical trials. These results suggest that a proportion of never-smoker patients with squamous
non-small cell lung cancer may be responsive to immunotherapy. Other factors, such as the tumor mutational load and
the status of programmed death-ligand 1, anaplastic lymphoma kinase, and epidermal growth factor receptor, might play
a potential key role.
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Introduction
Non-small cell lung cancer (NSCLC) accounts for 85%
of newly diagnosed cases of lung cancers, with squa-
mous NSCLC comprising 20%–30% of these.1,2 For
many years, docetaxel has been the standard of care for
advanced squamous NSCLC following failure of first-
line systemic therapy, despite providing limited clinical
benefit.2 Because squamous NSCLC is less likely than
non-squamous NSCLC to be driven by specific gene
mutations, molecularly targeted agents, such as inhibi-
tors of epidermal growth factor receptor (EGFR) or
anaplastic lymphoma kinase (ALK) that have improved
survival in non-squamous NSCLC, are ineffective or
rarely indicated in squamous NSCLC.3,4
Results of the randomized phase III CheckMate 017
study demonstrated that nivolumab, a fully human
programmed death 1 (PD-1) immune checkpoint inhi-
bitor antibody, provided long-term survival benefit in
patients with previously treated advanced squamous
NSCLC.5 This trial, conducted in patients after failure
of first-line platinum-based chemotherapy, found a
41% reduction in the risk of death with nivolumab
compared with docetaxel (hazard ratio (HR) 0.59; 95%
confidence interval (CI): 0.44–0.79; p\ 0.001); median
overall survival (OS) was 9.2months with nivolumab
compared with 6.0months with docetaxel. Similar ben-
efit was also reported in patients with previously
treated advanced non-squamous NSCLC who were
treated with nivolumab in the randomized phase III
CheckMate 057 study.6 These results led to the
approval of nivolumab in the United States and the
European Union for locally advanced or metastatic
squamous and non-squamous NSCLC with disease
progression during or after prior chemotherapy.7,8
Nearly a quarter of all cases of lung cancer (mostly
NSCLC) occur in never-smokers, and these have been
proposed as a distinct disease entity based on clinical
characteristics and possible etiologic factors. Lung can-
cer in never-smokers is more common in females, is
often driven by specific actionable gene mutations (e.g.
EGFR, ALK), has a better prognosis than does
smoking-related lung cancer, and has adenocarcinoma
as the predominant histologic type.9–11 Tumors in
never-smokers with NSCLC have also been shown to
have a lower mutational load than those in smokers.12
Differences in the mutational landscape and conse-
quent neoantigen formation have been proposed as an
explanation for higher rates of response among current
and former smokers than never-smokers in trials of
PD-1 checkpoint inhibitor therapies, including nivolu-
mab, although these analyses were limited by small
numbers of never-smokers.5,6,12–19
An international nivolumab expanded access program
(EAP) in advanced squamous NSCLC allowed patients
who were unable to take part in local nivolumab clinical
trials to gain access to treatment before it became com-
mercially available. EAPs have relatively broad entry cri-
teria and thereby mimic routine clinical practice more
closely than does the controlled clinical trial setting. An
analysis of preliminary data from the entire Italian cohort
of patients with squamous NSCLC enrolled in the nivolu-
mab NSCLC EAP has been reported elsewhere.20 Here,
we present preliminary efficacy and safety data from the
subgroup of never-smokers in this Italian cohort.
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Patients aged 18 years or older with stage IIIB or IV
squamous NSCLC that had been histologically or cyto-
logically confirmed at the participating institution were
eligible for enrollment. All patients had disease pro-
gression or recurrence during or after one or more
prior systemic treatments for advanced or metastatic
disease. Patients who developed recurrent disease
within 6months of completing platinum-based adju-
vant, neoadjuvant, or definitive chemoradiation ther-
apy for locally advanced disease were also eligible.
Patients with treated central nervous system metastases
that had been stable for at least 2weeks were eligible,
provided that they did not require corticosteroids or
were on a stable or decreasing dose of no more than
10mg prednisone daily (or an equivalent). In addition,
patients were required to have an Eastern Cooperative
Oncology Group (ECOG) performance status of 2 or
less; have completed prior treatment with chemother-
apy, tyrosine kinase inhibitors, tumor vaccine, cyto-
kines, or palliative radiotherapy at least 2weeks before
beginning nivolumab therapy, with resolution of all
adverse events to baseline or stabilization; have ade-
quate hematologic, hepatic, and renal function; and
have life expectancy of at least 6weeks.
Patients were excluded if they had active, known, or
suspected autoimmune disease, with the exception of
type 1 diabetes mellitus, residual hypothyroidism due to
an autoimmune condition requiring hormone replace-
ment therapy, or psoriasis not requiring systemic treat-
ment. Patients with carcinomatous meningitis, prior
therapy with any drug specifically targeting T-cell co-
stimulation or checkpoint pathways, symptomatic
interstitial lung disease, HIV infection, or prior treat-
ment in any nivolumab clinical trial were also excluded.
The assessment of EGFR, ALK, or programmed
death-ligand 1 (PD-L1) was not required before
enrollment.
Study design and treatment
Nivolumab was made available on physician request
through the EAP. The EAP guidelines were approved
at each participating center, and participating physi-
cians had to comply with generally accepted good clini-
cal practice and ethical standards. All patients provided
written, informed consent to their participation in the
program.
Nivolumab 3mg/kg was administered intravenously
every 2weeks for up to 24months. Treatment could be
discontinued due to disease progression, unacceptable
toxicity, or withdrawal of consent. Although no reduc-
tions in nivolumab dosing were allowed, the treatment
could be delayed in the event of toxicity. Nivolumab
treatment could be continued beyond progression if, in
the opinion of the investigator, the patient was deriving
clinical benefit in the absence of rapid disease progres-
sion, the study drug was tolerated, performance status
was stable, and treatment would not delay any inter-
vention to prevent serious complications of disease
progression.
Assessments
The EAP had no prespecified endpoints, but investi-
gators were encouraged to make every effort to docu-
ment the objective disease progression. Efficacy data
collected included investigator-assessed objective
tumor response, date of progression, and survival
information.
Safety was monitored by continuous assessment of
adverse events, physical examination, ECOG perfor-
mance status, hematology and clinical chemistry tests,
and thyroid function tests according to local regulations
and standards of care. Adverse events were graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0,
with the causal relationship to treatment determined by
the investigators.
Statistical analysis
All patients who received at least one dose of nivolu-
mab were included in both the efficacy and safety anal-
yses. Never-smokers were defined on the basis of
patient-reported information. Objective response rate
(ORR), disease control rate (DCR; defined as the com-
bined rates of complete response, partial response, and
stable disease), progression-free survival (PFS), and OS
were evaluated. PFS and OS were estimated using the
Kaplan–Meier method, and 95% CIs were derived
using the Greenwood formula of asymptotic variance.
PFS was calculated as the time between the start of
nivolumab treatment and any evidence of progressive
disease, or death, whichever occurred first.
Results
Patients and treatment
Between April and September 2015, 371 patients were
enrolled in the EAP at 96 centers in Italy and received
at least one dose of nivolumab. Among the 31 patients
(8%) who were never-smokers, 3 had tumors with ade-
nosquamous histology. In the never-smoker group and
overall EAP cohort, 39% and 80% were male, respec-
tively; the median age (range) was 66 (31–82) and 68
(31–91) years; 61% and 64% had ECOG performance
status 1–2; and 68% and 56% received at least two
prior therapies (Table 1).
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Overall, patients received a median of six doses of
nivolumab (range, 1–22), with a median follow-up of
7.1months (range: 0.1–16.4). The median number of
nivolumab doses among never-smokers was 6 (range,
1–21), and the median follow-up was 7.0months (range,
1.1–13.6). In total, 24 never-smokers (77%) had discon-
tinued treatment at the time of analysis mostly because
of progressive disease (n=13; 54%) or death (n=6;
25%; Table 2).
Efficacy
Among never-smokers, the ORR was 23%, which
included seven (23%) partial responses. An additional
seven patients (23%) had stable disease, and the DCR
for the never-smokers group was 45% (Table 3). In the
overall EAP population, the ORR was 18%, including
4 complete responses (1%) and 63 partial responses
(17%), an additional 108 patients (29%) had stable dis-
ease, giving a DCR of 47% (Table 3). Among 14 never-
smokers with available EGFR data, 3 had tumor EGFR
mutations, and among 12 never-smokers with available
ALK data, 1 had a tumor ALK rearrangement. These
four patients with tumor driver mutations each had
progressive disease as their best objective response.
The three patients with EGFR mutations received
therapy with erlotinib, gefitinib, and afatinib, respec-
tively, before nivolumab. The patient with ALK rear-
rangement was not treated with any ALK inhibitors
before the enrollment in the EAP.
No data were available on the PD-L1 status.
For never-smokers and the overall EAP population,
the 1-year OS rates were 51% and 39%, respectively,
while the median OS was 12.1months (95% CI: 3.7–
20.4) and 7.9months (95% CI: 6.2–9.6; Figure 1(a)).
The 1-year PFS rates were 30% and 27% for never-
smokers and the overall EAP population, respectively,
while the median PFS was 3.5months (95% CI: 0.0–
7.1) and 4.2months (95% CI: 3.4–5.0; Figure 1(b)),
respectively.
Safety
Any-grade and grade 3–4 treatment-related adverse
events occurred in 12 (39%) and 3 (10%) never-smo-
kers, respectively, compared with 109 (29%) and 21
patients (6%) in the overall EAP population (Table 4).
Among never-smokers, the most common (ø 5%)
treatment-related adverse events of any grade were fati-
gue/asthenia (13%; n=4), rash (13%; n=4), pain
(10%; n=3), anemia (6%; n=2), diarrhea (6%;





Median age, years (range) 66 (31–82) 68 (31–91)
ø 75 years 2 (6) 70 (19)
Gender
Male 12 (39) 298 (80)
Female 19 (61) 73 (20)
Smoking status
Smoker 2 83 (22)
Former smoker 2 225 (61)
Never-smoker 31 (100) 31 (8)
Unknown 2 32 (9)
ECOG performance status
0 12 (39) 134 (36)
1 19 (61) 215 (58)
2 0 22 (6)
Site of metastasis
Central nervous system 5 (16) 37 (10)
Liver 8 (26) 63 (17)
Bone 13 (42) 120 (32)
Number of prior systemic therapies
1 10 (32) 162 (44)
2 11 (35) 120 (32)
3 5 (16) 68 (18)
ø 4 5 (16) 21 (6)
ECOG: Eastern Cooperative Oncology Group.
Data are presented as n (%) unless otherwise specified.





Discontinued treatment 24 (77) 281 (76)
Reason for discontinuation
Progressive disease 13 (54) 167 (59)
Death 6 (25) 68 (24)
Adverse event or serious
adverse event
4 (17) 26 (9)
Other 1 (4) 20 (7)
Data are presented as n (%).





Objective response rate 7 (23) 67 (18)
95% CI 8237 14222
Disease control ratea 14 (45) 175 (47)
95% CI 28263 42252
Best response
Complete response 0 4 (1)
Partial response 7 (23) 63 (17)
Stable disease 7 (23) 108 (29)
Progressive disease 16 (52) 189 (51)
Could not be determined 1 (3) 7 (2)
CI: confidence interval.
Data are presented as n (%) unless otherwise specified.
aDefined as the combined rate of complete response, partial response,
and stable disease.
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n=2), elevated transaminases (6%), and pyrexia (6%;
n=2). Grade 3–4 treatment-related adverse events in
never-smokers comprised increased transaminases
(n=2; 6%) and diarrhea (n=1; 3%). No treatment-
related deaths were reported.
Of 24 never-smokers who discontinued nivolumab
treatment, 4 (17%) did so as a result of adverse events,
compared with 26 of 281 patients (9%) in the overall
EAP population (Table 2). Discontinuations due to
treatment-related adverse events occurred in 8% (2/24)
Figure 1. Kaplan–Meier estimates of overall survival (a) and progression-free survival (b).
OS: overall survival; PFS: progression-free survival.
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of never-smokers and 5% (14/281) of the overall EAP
population. Treatment-related adverse events leading
to discontinuation among never-smokers were hepatic
toxicity and bilateral exophthalmos (n=1, each), while
those among the overall EAP population were pneumo-
nitis (n=3); diarrhea, hepatotoxicity, and skin toxicity
(n=2, each); and bilateral exophthalmos, dyspnea,
headache, paralytic ileus, and psoriasis (n=1, each).
Treatment-related adverse events of immune etiology
(‘‘select adverse events’’) were managed using protocol-
defined toxicity management algorithms.
Discussion
Never-smokers with advanced squamous NSCLC in the
Italian cohort of this EAP demonstrated benefits with
nivolumab therapy comparable to those in the overall
EAP population and largely mirrored the efficacy
observed in the nivolumab arm of the phase III
CheckMate 017 trial in patients with advanced squamous
NSCLC (median OS, 9.2months; ORR, 20%; DCR,
49%).5 Contrasting with results from controlled studies
showing that never-smokers with advanced NSCLC as a
whole seem to benefit less from immunotherapy than
smokers,6,13,15 our data suggest that a proportion of
never-smokers with squamous NSCLC may be respon-
sive to nivolumab. However, the patient populations of
the nivolumab studies in which response or survival dif-
fered according to smoking history comprised exclusively
non-squamous NSCLC, as in the phase III CheckMate
057 trial, or had greater numbers of patients with non-
squamous than squamous histology, as well as relatively
small numbers of never-smokers.6,12,13,15,20–22
In this study, no data were available on the PD-L1
status because at the time in which it was conducted,
the assessment of PD-L1 was not a standard practice in
Italy and it was not an inclusion criterion of the EAP.
Interestingly all four never-smokers who tested posi-
tive for recognized NSCLC driver mutations (three with
EGFR mutations and one with an ALK rearrangement)
had progressive disease as their best overall response.
Specific driver mutations are implicated less commonly
in NSCLC with squamous than non-squamous histol-
ogy, as observed here. In patients with driver muta-
tions, mutational load tends to be lower, with decreased
levels of neoantigens, and immunotherapy with PD-
inhibition is expected to be less effective.9–11,18
Safety was comparable between never-smokers and
the overall EAP population and was consistent with
results previously reported for the nivolumab arm in
CheckMate 017.5 Most adverse events were mild to
moderate, and the proportion of EAP never-smokers
who had grade 3–4 treatment-related adverse events
(10%) was comparable to that found in the overall
EAP population (6%), as well as in the nivolumab arm
of CheckMate 017 (7%). The proportion of EAP never-
smokers who discontinued therapy due to treatment-
related adverse events (8%) was also similar to that in
Table 4. Treatment-related adverse events occurring in ø 1% of patients.
Adverse event, n (%) Never-smokers (n = 31) All patients (N = 371)
Any grade Grade 3–4 Any grade Grade 3–4
Any adverse event 12 (39) 3 (10) 109 (29) 21 (6)
General
Fatigue/asthenia 4 (13) 0 24 (6) 2 (1)
Pyrexia 2 (6) 0 10 (3) 0
Lack of appetite/anorexia 1 (3) 0 9 (2) 0
Skin and mucosal 4 (13) 0 42 (11) 5 (1)
Rash 4 (13) 0 31 (8) 3 (1)
Gastrointestinal 2 (6) 1 (3) 27 (7) 4 (1)
Diarrhea 2 (6) 1 (3) 18 (5) 4 (1)
Hepatic/pancreatic 2 (6) 2 (6) 8 (2) 4 (1)
Transaminase increase 2 (6) 2 (6) 6 (2) 4 (1)
Lipase/amylase increase 0 0 2 (1) 0
Pain 3 (10) 0 19 (5) 3 (1)
Hematologic 2 (6) 0 10 (3) 1 (\1)
Anemia 2 (6) 0 9 (2) 1 (\1)
Endocrine 1 (3) 0 16 (4) 1 (\1)
Hypothyroidism 1 (3) 0 10 (3) 0
Hyperthyroidism 0 0 5 (1) 1 (\1)
Respiratory/pulmonary 0 0 12 (3) 4 (1)
Pneumonitis 0 0 3 (1) 1 (\1)
Data are presented as n (%).
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the overall EAP population (5%) and the nivolumab
arm of CheckMate 017 (3%).
This report presents the most extensive real-world
clinical experience with nivolumab in never-smokers
with advanced squamous NSCLC in current practice
to date, and the proportion of never-smokers in the
Italian EAP cohort of previously treated patients with
advanced squamous NSCLC was comparable to that
reported in the nivolumab arm of CheckMate 017 (8%
vs 7%).5 In summary, nivolumab provided clinical
activity coupled with a manageable safety profile in
never-smokers. While the study was limited by small
patient numbers and its observational design, the effi-
cacy and safety profiles of nivolumab among never-
smokers without driver mutations in a real-world set-
ting were consistent with those obtained in the broader
population of patients (including former and current
smokers) with squamous NSCLC, including those in
controlled clinical trials.5 Among patients with
advanced NSCLC, never-smokers are of particular
interest, because as a group, they appear to derive less
benefit from immunotherapy versus smokers, who have
a higher mutational load.6,13,15 Although further study
is needed to clarify the association between nivolumab
response and smoking history, these results suggest that
never-smokers with squamous NSCLC, especially those
without driver mutations, may be a distinct patient
subgroup. Other factors such as the assessment of the
tumor mutational load and the status of PD-L1, ALK,
and EGFR could play a role for the selection of never-
smokers with advanced squamous NSCLC that are
likely to respond to immunotherapy.
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